LOGIN
ID
PW
MemberShip
2025-07-19 07:58
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Roche 2018 Annualreport
Roche 2018 Annualreport
2019-12-23
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2019-12-23
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
2019-11-15
Risk-Sharing Agreements in the EU: A Systematic Review
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
2019-11-15
Managed Entry Agreements for
Managed Entry Agreements for Oncology Drugs
2019-11-15
OPINION
[Reporter's View] Bio policy should remain consistent
Reporter's view |
Kim, Jin-Gu
[Reporter's View] Gov¡¯t cooperation leads to a price cut?
Reporter's view |
Eo, Yun-Ho
[Reporter¡¯s View]Biotech¡¯s responsible approach to failure
Reporter's view |
Cha, Jihyun
INTERVIEW
V-olet challenges to become a blockbuster fat-destroying inj
Kim Seul-ki, PM of Daewoong Pharmaceutical's Nabota Business Team
'Viatris will lead market with innovation and leadership'
Bill Schuster, Representative Director & Country Manager of Viatris Korea
"Livtencity offers new CMV trt for transplant patients"
Dr. Sang-Oh Lee, professor at Seoul Asan Medical Center's Department of Infectious Diseases
¡®SGLT2i+TZD promising for diabetics with fatty liver risk¡¯
Cheol-Young Park, Professor of Endocrinology at Kangbuk Samsung Hospital
Hemlibra shows long-term efficacy and safety in hemophilia
Long-term prevention of bleeding episodes
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
[Reporter¡¯s View]Biotech¡¯s responsible approach to failure
2
Daiichi Sankyo and Ono Pharmaceutical see surge in sales
3
Orphan drug 'Bylvay Cap' wins reimb approval after reeval
4
Oral lung cancer drug market race
5
Pharmaceutical exports to U.S. have surged by 46%
6
[Reporter's View] Bio policy should remain consistent
7
Polivy¡¯s reimbursement for DLBLC will soon be reviewed
8
Potential changes to reimb policy for new anticancer drugs
9
Various immunotherapies attempt to treat Alzheimer¡¯s
10
Aftermath of Januvia's price cut¡¦MSD-CKD compensation fight